Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients
- Sponsor
- ARCAGY/ GINECO GROUP
- Study ID
- NCT04152941
- Status
- Completed
Conditions
- Relapsed Ovarian Cancers Patients
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Olaparib — DRUGPatients with histologically confirmed ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer treated with olaparib in a real life-setting, between May 2014 to March 2017, whatever the line of therapy
Study Details
This is a national, multi center, retrospective observational cohort study that will be carried out by reviewing the medical records of patients with relapsed epithelial ovarian, fallopian tube, or peritoneal cancer treated with olaparib following response to platinum-based chemotherapy.
Key Dates
- Start date
- Oct 11, 2018
- Status verified
- Sep 2023
- Primary completion
- Feb 11, 2020
- Completion
- Feb 11, 2020
Study Design
- Enrollment
- 130 participants (actual)
Primary Outcome Measure
progression free survival (PFS) [ Time Frame: through study completion, an average of 1 year ]